Pentoxifylline suppresses transduction by HIV-1-based vectors

Intervirology

Volumn 50, Issue 5, 2007, Pages 377-386

  Smith, Johanna A ^a   Nunnari, Giuseppe ^a   Preuss, Mirjam ^a   Pomerantz, Roger J ^a   Daniel, René ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

ATR; DNA repair; Human immunodeficiency virus type 1; Pentoxifylline

Indexed keywords

ATR PROTEIN; PENTOXIFYLLINE; VIRUS VECTOR;

ARTICLE; CONTROLLED STUDY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL CYCLE PROTEINS; CELL LINE; GENETIC VECTORS; HIV-1; HUMANS; PENTOXIFYLLINE; PROTEIN-SERINE-THREONINE KINASES; TRANSDUCTION, GENETIC; VIRUS INTEGRATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 35548953640     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000109752     Document Type: Article

References (50)

1. Hauber I, Bevec D, Heukeshoven J, Kratzer F, Horn F, Choidas A, Harrer T, Hauber J: Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy. J Clin Invest 2005;115:76-85.
2. Daniel R, Kao G, Taganov K, Greger JG, Favorova O, Merkel G, Yen TJ, Katz RA, Skalka AM: Evidence that the retroviral DNA integration process triggers an ATR-dependent DNA damage response. Proc Natl Acad Sci USA 2003;100:4778-4783.
3. Daniel R, Katz RA, Merkel G, Hittle JC, Yen TJ, Skalka AM: Wortmannin potentiates integrase-mediated killing of lymphocytes and reduces the efficiency of stable transduction by retroviruses. Mol Cell Biol 2001;21:1164-1172.
4. Daniel R, Katz RA, Skalka AM: A role for DNA-PK in retroviral DNA integration. Science 1999;284:644-647.
5. Daniel R, Marusich E, Argyris E, Zhao RY, Skalka AM, Pomerantz RJ: Caffeine inhibits human immunodeficiency virus type 1 transduction of nondividing cells. J Virol 2005;79:2058-2065.
6. Lau A, Swinbank KM, Ahmed PS, Taylor DL, Jackson SP, Smith GC, O'Connor MJ: Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase. Nat Cell Biol 2005;7:493-500.
7. Skalka AM, Katz RA: Retroviral DNA integration and the DNA damage response. Cell Death Differ 2005;12(suppl 1):971-978.
8. Nunnari G, Argyris E, Fang J, Mehlman KE, Pomerantz RJ, Daniel R: Inhibition of HIV-1 replication by caffeine and caffeine-related methylxanthines. Virology 2005;335:177-184.
9. Dezube BJ: Pentoxifylline for the treatment of infection with human immunodeficiency virus. Clin Infect Dis 1994;18:285-287.
10. Biswas DK, Dezube BJ, Ahlers CM, Pardee AB: Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-kappa B action. J Acquir Immune Defic Syndr 1993;6:778-786.
11. Clerici M, Piconi S, Balotta C, Trabattoni D, Capetti A, Fusi ML, Ruzzante S, Longhi R, Colombo MC, Moroni M, Milazzo F: Pentoxifylline improves cell-mediated immunity and reduces human immunodeficiency virus (HIV) plasma viremia in asymptomatic HIV-seropositive persons. J Infect Dis 1997;175:1210-1215.
12. Fazely F, Dezube BJ, Allen-Ryan J, Pardee AB, Ruprecht RM: Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells. Blood 1991;77:1653-1656.
13. Mhashilkar AM, Biswas DK, LaVecchio J, Pardee AB, Marasco WA: Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kappa B antagonists. J Virol 1997;71:6486-6494.
14. Brown FL, Tahaoglu E, Graham GJ, Maio JJ: Inducible transcriptional activation of the human immunodeficiency virus long terminal repeat by protein kinase inhibitors. Mol Cell Biol 1993;13:5245-5254.
15. Navarro J, Punzon MC, Pizarro A, Fernandez-Cruz E, Fresno M, Munoz-Fernandez MA: Pentoxifylline inhibits acute HIV-1 replication in human T cells by a mechanism not involving inhibition of tumour necrosis factor synthesis or nuclear factor-kappa B activation. AIDS 1996;10:469-475.
16. Daniel R, Ramcharan J, Rogakou E, Taganov KD, Greger JG, Bonner W, Nussenzweig A, Katz RA, Skalka AM: Histone H2AX is phosphorylated at sites of retroviral DNA integration but is dispensable for postintegration repair. J Biol Chem 2004;279:45810-45814.
17. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS: HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990;61:213-222.
18. Butler SL, Hansen MS, Bushman FD: A quantitative assay for HIV DNA integration in vivo. Nat Med 2001;7:631-634.
19. Wong ML, Medrano JF: Real-time PCR for mRNA quantitation. Biotechniques 2005;39:75-85.
20. Nunnari G, Otero M, Dornadula G, Vanella M, Zhang H, Frank I, Pomerantz RJ: Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections. AIDS 2002;16:39-45.
21. Bohm L, Roos WP, Serafin AM: Inhibition of DNA repair by pentoxifylline and related methylxanthine derivatives. Toxicology 2003;193:153-160.
22. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, Abraham RT: Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999;59:4375-4382.
23. Brown EJ, Baltimore D: ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev 2000;14:397-402.
24. Cortez D, Wang Y, Qin J, Elledge SJ: Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999;286:1162-1166.
25. Cliby WA, Roberts CJ, Cimprich KA, Stringer CM, Lamb JR, Schreiber SL, Friend SH: Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J 1998;17:159-169.
26. Durocher D, Jackson SP: DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol 2001;13:225-231.
27. O'Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA, Goodship JA: A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet 2003;33:497-501.
28. Goodship J, Gill H, Carter J, Jackson A, Splitt M, Wright M: Autozygosity mapping of a Seckel syndrome locus to chromosome 3q22. 1-q24. Am J Hum Genet 2000;67:498-503.
29. Chanan-Khan A, Holkova B, Perle MA, Reich E, Wu CD, Inghirami G, Takeshita K: T-cell clonality and myelodysplasia without chromosomal fragility in a patient with features of Seckel syndrome. Haematologica 2003;88:ECR14.
30. Andreassen PR, D'Andrea AD, Taniguchi T: ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev 2004;18:1958-1963.
31. Alderton GK, Joenje H, Varon R, Borglum AD, Jeggo PA, O'Driscoll M: Seckel syndrome exhibits cellular features demonstrating defects in the ATR-signalling pathway. Hum Mol Genet 2004;13:3127-3138.
32. Borglum AD, Balslev T, Haagerup A, Birkebaek N, Binderup H, Kruse TA, Hertz JM: A new locus for Seckel syndrome on chromosome 18p11.31-q11.2. Eur J Hum Genet 2001;9:753-757.
33. Faivre L, Le Merrer M, Lyonnet S, Plauchu H, Dagoneau N, Campos-Xavier AB, Attia-Sobol J, Verloes A, Munnich A, Cormier-Daire V: Clinical and genetic heterogeneity of Seckel syndrome. Am J Med Genet 2002;112:379-383.
34. Kilinc MO, Ninis VN, Ugur SA, Tuysuz B, Seven M, Balci S, Goodship J, Tolun A: Is the novel SCKL3 at 14q23 the predominant Seckel locus? Eur J Hum Genet 2003;11:851-857.
35. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, Donehower LA, Elledge SJ: Chk1 is an essential kinase that is regulated by ATR and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000;14:1448-1459.
36. Dehart JL, Andersen JL, Zimmerman ES, Ardon O, An DS, Blackett J, Kim B, Planelles V: The ataxia telangiectasia-mutated and Rad3-related protein is dispensable for retroviral integration. J Virol 2005;79:1389-1396.
37. Ariumi Y, Turelli P, Masutani M, Trono D: DNA damage sensors ATM, ATR, DNAPKcs, and PARP-1 are dispensable for human immunodeficiency virus type 1 integration. J Virol 2005;79:2973-2978.
38. Downs JA, Lowndes NF, Jackson SP: A role for Saccharomyces cerevisiae histone H2A in DNA repair. Nature 2000;408:1001-1004.
39. Falck J, Coates J, Jackson SP: Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 2005;434:605-611.
40. Shiloh Y: ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 2001;11:71-77.
41. Zhou BB, Elledge SJ: The DNA damage response: putting checkpoints in perspective. Nature 2000;408:433-439.
42. Daniel R, Pomerantz RJ: ATM: HIV-1's Achilles heel? Nat Cell Biol 2005;7:452-453.
43. Biswas DK, Ahlers CM, Dezube BJ, Pardee AB: Pentoxifylline and other protein kinase C inhibitors down-regulate HIV-LTR NFkappa B induced gene expression. Mol Med 1994;1:31-43.
44. Dezube BJ, Lederman MM: Pentoxifylline for the treatment of HIV infection and its complications. J Cardiovasc Pharmacol 1995;25(suppl 2):S139-S142.
45. Dezube BJ, Pardee AB, Chapman B, Beckett LA, Korvick JA, Novick WJ, Chiurco J, Kasdan P, Ahlers CM, Ecto LT, et al: Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group. J Acquir Immune Defic Syndr 1993;6:787-794.
46. Dezube BJ, Lederman MM, Spritzler JG, Chapman B, Korvick JA, Flexner C, Dando S, Mattiacci MR, Ahlers CM, Zhang L, et al: High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. J Infect Dis 1995;171:1628-1632.
47. Luke DR, McCreedy BJ, Sarnoski TP, Bookout JB, Johnston AM, Lell JE, Wiggan EB, Bell N, Limjuco RA, Guthrie KI, et al: Phase I/II study of pentoxifylline with zidovudine on HIV-1 growth in AIDS patients. Int J Clin Pharmacol Ther Toxicol 1993;31:343-350.
48. Luke DR, Sarnoski TP, Bell N, Dennis S: Influence of pentoxifylline on renal function in HIV-seropositive patients. Ren Fail 1993;15:181-188.
49. Wallis RS, Johnson JL, Okwera A, Nsubuga P, Whalen CC, Mugerwa RD, Ellner JJ: Pentoxifylline in human immunodeficiency virus-positive tuberculosis: safety at 4 years. J Infect Dis 1998;178:1861.
50. Wallis RS, Nsubuga P, Whalen C, Mugerwa RD, Okwera A, Oette D, Jackson JB, Johnson JL, Ellner JJ: Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial. J Infect Dis 1996;174:727-733.